Serving leading biopharmaceutical companies globally:
Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing
Serving leading biopharmaceutical companies globally:
Generated: October 23, 2017
Which drugs does patent 8,207,297 protect, and when does it expire?
| Title: | Compounds for enzyme inhibition |
| Abstract: | Peptide-based compounds including heteroatom-containing, three-membered rings efficiently and selectively inhibit specific activities of N-terminal nucleophile (Ntn) hydrolases. The activities of those Ntn having multiple activities can be differentially inhibited by the compounds described. For example, the chymotrypsin-like activity of the 20S proteasome may be selectively inhibited with the inventive compounds. The peptide-based compounds include at least three peptide units, an epoxide or aziridine, and functionalization at the N-terminus. Among other therapeutic utilities, the peptide-based compounds are expected to display anti-inflammatory properties and inhibition of cell proliferation. |
| Inventor(s): | Smyth; Mark S. (Foster City, CA), Laidig; Guy J. (Menlo Park, CA) |
| Assignee: | Onyx Therapeutics, Inc. (South San Francisco, CA) |
| Application Number: | 13/334,469 |
|
Patent Claim Types: see list of patent claims | Use; Process; Composition; Formulation; Dosage form; Compound; |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-002 | Jun 3, 2016 | RX | Yes | No | ► Subscribe | ► Subscribe | Y | Y | |||
Onyx Therap | KYPROLIS | carfilzomib | POWDER;INTRAVENOUS | 202714-001 | Jul 20, 2012 | RX | Yes | Yes | ► Subscribe | ► Subscribe | Y | Y | |||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
Export unavailable in trial.
Subscribe for complete access.
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 7,232,818 | Compounds for enzyme inhibition | ► Subscribe | |||||||||||||
| 8,324,174 | Compounds for enzyme inhibition | ► Subscribe | |||||||||||||
| 8,207,125 | Compounds for enzyme inhibition | ► Subscribe | |||||||||||||
| 8,198,270 | Compounds for proteasome enzyme inhibition | ► Subscribe | |||||||||||||
| 7,491,704 | Compounds for enzyme inhibition | ► Subscribe | |||||||||||||
| 8,207,124 | Compounds for enzyme inhibition | ► Subscribe | |||||||||||||
| 8,207,126 | Compounds for enzyme inhibition | ► Subscribe | |||||||||||||
| 7,417,042 | Compounds for enzyme inhibition | ► Subscribe | |||||||||||||
| 8,129,346 | Compounds for enzyme inhibition | ► Subscribe | |||||||||||||
| 8,207,127 | Compounds for enzyme inhibition | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
| Country | Document Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Austria | 494298 | ► Subscribe | |||||||||||||
| Austria | 496062 | ► Subscribe | |||||||||||||
| Australia | 2005238445 | ► Subscribe | |||||||||||||
| Australia | 2005271232 | ► Subscribe | |||||||||||||
| Australia | 2005295183 | ► Subscribe | |||||||||||||
| Australia | 2012203602 | ► Subscribe | |||||||||||||
| Australia | 2012211349 | ► Subscribe | |||||||||||||
| Brazil | PI0509879 | ► Subscribe | |||||||||||||
| Brazil | PI0514102 | ► Subscribe | |||||||||||||
| Canada | 2562411 | ► Subscribe | |||||||||||||
| This preview shows a limited data set Subscribe for full access, or try a Trial | |||||||||||||||
The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws,
it is advisable to have patent counsel verify freedom to operate.
Export unavailable in trial.
Subscribe for complete access.
Serving leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Follow DrugPatentWatch:
Join the 23,015 others who get our Drug Patent Expiration Alerts:
